Agouron Pharmaceuticals (AGPH) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Agouron Pharmaceuticals (AGPH)

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Oliver & Co who wrote (3192)	12/7/1997 3:13:00 PM
From: JOHN W.	of 6136

NEWTOWN, Pa., Dec 5 (Reuters) - CollaGenex Pharmaceuticals Inc said Friday that the National Cancer Institute has filed an Investigational New Drug application for Metastat, the company's lead compound for the inhibition of cancer invasion and metastasis. It is anticipated that clinical studies in patients with metastatic cancer will begin early in 1998, pending approval by the FDA. Metastat is the first of CollaGenex's novel ''chemically modified tetracyclines,'' developed in conjunction with a laboratory at the State University of New York at Stony Brook. These compounds, which have been chemically stripped of their antimicrobial properties, behave as inhibitors of a key group of enzymes known as matrix metalloproteinases (''MMPs''). It said the National Cancer Institute ''has supported this program throughout.'' MMPs are involved in the processes which cause cancer to spread, or metastasize, in the human body.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next